SYROS PHARMACEUTICALS

At Syros, we are redefining the power of small molecules to control the expression of genes, and in doing so, we aim to make a profound difference in the lives of patients and their families... We are advancing a clinical pipeline of small-molecule medicines that control the expression of genes to treat cancer and genetic diseases. Our pipeline includes three investigational medicines in clinical development and multiple programs in preclinical development and discovery research... Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including tamibarotene (formerly SY-1425), a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome..

Also known as: Syros Pharmaceuticals, Inc.

Primary location: Cambridge United States